Vitamin D in older adults: the need to specify standard values with respect to cognition

Cédric Annweiler1,2* and Olivier Beauchet1

1 Department of Neuroscience, Division of Geriatric Medicine and Memory Clinic, Angers University Hospital, UPRÉS EA 4638, University of Angers, UNAM, Angers, France
2 Department of Medical Biophysics, Schulich School of Medicine and Dentistry, Robarts Research Institute, The University of Western Ontario, London, ON, Canada

*Correspondence: ceannweiler@chu-angers.fr

Edited by:
Claudia Perez-Cruz, Centro de Investigaciones y Estudios Avanzados, Mexico

Reviewed by:
Carlos Beas-Zarate, Universidad de Guadalajara Mexico, Mexico

Keywords: cognition, dementia, older adults, standard, threshold, vitamin D

Besides its classical function of bone metabolism regulation, vitamin D exhibits multiple biological targets mediated by its nuclear hormone receptor, the vitamin D receptor (VDR) (Holick, 2007; Kalu-eff and Tuohimaa, 2007; Annweiler et al., 2010a, 2011b). Specific actions on target organs such as the central nervous system (CNS) have been described, providing evidence for a neurosteroid action of vitamin D (Kaluff and Tuohimaa, 2007; Annweiler et al., 2010a). Consistently, older adults with lower serum 25-hydroxyvitamin D (25OHD) concentrations exhibit more often and more severe cognitive decline (Annweiler et al., 2009, 2013a,b; Balion et al., 2012; Egen et al., 2012). At that point, an important issue to be clarified is to determine what concentration of 25OHD is associated with adverse effects in the brain.

**MOST OLDER ADULTS HAVE LOW LEVELS OF VITAMIN D**

At least one billion people have hypovitaminosis D worldwide (Holick, 2007). Even if all adults can be affected by hypovitaminosis D, older adults have the greatest risk, especially those living in institution (Annweiler et al., 2011b). For illustration, in Europe and the United States, up to 90% of older adults have hypovitaminosis D (Annweiler et al., 2011b). This high prevalence of hypovitaminosis D in the elderly is due to the high frequency of mechanisms leading to hypovitaminosis D, first and foremost the reduction of cutaneous synthesis (decreased exposure to sunlight due to loss of functionality, and decreased capacity of skin synthesis due to the 25% reduction of 7-dehydrocholesterol compared to younger adults) (Holick et al., 1989). Hypovitaminosis D may also result from the alteration of the metabolism of vitamin D (hepatic and kidney failures) (Dusso et al., 2005), inadequate food intake (Hollis and Wagner, 2004), reduced bioavailability (malabsorption syndrome, obesity with sequestration of vitamin D in the fat) (Lo et al., 1983), increased catabolism (regular use of antiepileptics, glucocorticoids, immunosuppressive drugs) (Zhou et al., 2006), and urinary loss of vitamin D (nephrotic syndrome) (Dusso et al., 2005).

The high prevalence of hypovitaminosis D in elderly population is also explained by the choice of the threshold defining hypovitaminosis D, which may vary between 10 and 30 ng/mL.

**THRESHOLD OF “NORMALITY” FOR SERUM VITAMIN D CONCENTRATION**

Vitamin D status is usually estimated by measuring serum 25OHD (Holick, 2007; Annweiler et al., 2011b). In general, there are two ways to establish reference values for a biological variable. The first one is based on the use of "population-based reference values," which comprises measuring a parameter in the reference population and calculating the reference interval in which there is 95% of the population. In the case of 25OHD, the reference values could not be generalized because they depend on non-modifiable environmental factors (e.g., season, local climate, latitude), modifiable life habits (e.g., clothing, eating habits, sun exposure), and non-modifiable parameters (e.g., ethnicity, skin pigmentation, skin thickness, and age). Moreover, it should be kept in mind that, in clinical practice, the dosage of 25OHD is prescribed to determine if patients need vitamin D supplementation to maintain their health. These values have therefore little interest for the clinicians.

The second method for calculating reference values of 25OHD is to define hypovitaminosis D as 25OHD levels for which there are some adverse health effects. These reference values are called "health-based reference values." There is an international consensus to use this kind of threshold in the case of 25OHD (Annweiler et al., 2011b). The determination of such a threshold remains yet complex because of the multiplicity of disorders caused by hypovitaminosis D. Thus, historically, "normality" was defined by the avoidance of bone adverse effects. It is classically recognized that there is no rickets or osteomalacia with serum 25OHD above 10 ng/mL (Basha et al., 2000), and no secondary hyperparathyroidism with serum 25OHD above 20 ng/mL (Basha et al., 2000). For now, the threshold at 10 ng/mL (25 nmol/L) remains consensus to define vitamin D deficiency (i.e., severe hypovitaminosis D) (Holick, 2007; Annweiler et al., 2011b), and the threshold at 20 ng/mL (50 nmol/L) is the one used by the World Health Organization to define vitamin D insufficiency (World Health Organization, 2003). However, more recently, it has been elegantly reported that serum 25OHD above 30 ng/mL (75 nmol/L) is required...
Vitamin D is able to enter the cerebrospinal fluid (CSF) and brain by crossing the blood–brain barrier via passive diffusion and additional specific carriers in the cerebral capillaries or the blood–CSF barrier in the plexus choroidoe (Holmøy et al., 2009). The concentration of 25OHD in the CSF positively correlates with that in the serum under physiological conditions (Holmøy et al., 2009). In situ, vitamin D exerts most of its actions through its nuclear hormone receptor, VDR, expressed in neuronal and glial cells of the CNS, especially the hippocampus, hypothalamus, cortex, and subcortex (Kaluderv and Tuohimaa, 2007; Annweiler et al., 2010a). The binding of vitamin D on the VDR triggers neuronal protection against several degenerative processes, including anti-inflammatory action (Moore et al., 2005), antioxidant effect (Ibi et al., 2001), control of calcium homeostasis by regulating the concentration of intracellular calcium in hippocampal neurons (Breuer et al., 2001), anti-atrophic effect by regulating neurotrophic agents (Brown et al., 2003), and attenuation of Aβ42 peptide accumulation (Yu et al., 2011) by stimulating the phagocytosis of Aβ peptide (Masoumi et al., 2009) together with enhancing brain-to-blood Aβ efflux transport at the blood–brain barrier (Ito et al., 2011). Moreover, vitamin D regulates the genetic expression of numerous neurotransmitters in the brain, including acetylcholine, dopamine, serotonin, and γ-aminobutyric acid, notably in the hippocampus (Kaluderv and Tuohimaa, 2007). These experimentally described neurosteroid properties of vitamin D may help, in the case of normalized vitamin D status, to address the decline of brain function in older adults, especially against cognitive decline (Annweiler and Beauchet, 2011).

VITAMIN D AND THE CENTRAL NERVOUS SYSTEM: PRECLINICAL EVIDENCE

Vitamin D is able to enter the cerebrospinal fluid (CSF) and brain by crossing the blood–brain barrier via passive diffusion and additional specific carriers in the cerebral capillaries or the blood–CSF barrier in the plexus choroidoe (Holmøy et al., 2009). The concentration of 25OHD in the CSF positively correlates with that in the serum under physiological conditions (Holmøy et al., 2009). In situ, vitamin D exerts most of its actions through its nuclear hormone receptor, VDR, expressed in neuronal and glial cells of the CNS, especially the hippocampus, hypothalamus, cortex, and subcortex (Kaluderv and Tuohimaa, 2007; Annweiler et al., 2010a). The binding of vitamin D on the VDR triggers neuronal protection against several degenerative processes, including anti-inflammatory action (Moore et al., 2005), antioxidant effect (Ibi et al., 2001), control of calcium homeostasis by regulating the concentration of intracellular calcium in hippocampal neurons (Breuer et al., 2001), anti-atrophic effect by regulating neurotrophic agents (Brown et al., 2003), and attenuation of Aβ42 peptide accumulation (Yu et al., 2011) by stimulating the phagocytosis of Aβ peptide (Masoumi et al., 2009) together with enhancing brain-to-blood Aβ efflux transport at the blood–brain barrier (Ito et al., 2011). Moreover, vitamin D regulates the genetic expression of numerous neurotransmitters in the brain, including acetylcholine, dopamine, serotonin, and γ-aminobutyric acid, notably in the hippocampus (Kaluderv and Tuohimaa, 2007). These experimentally described neurosteroid properties of vitamin D may help, in the case of normalized vitamin D status, to address the decline of brain function in older adults, especially against cognitive decline (Annweiler and Beauchet, 2011).

VITAMIN D AND COGNITION: EPIDEMIOLOGICAL EVIDENCE

Most studies on this topic have been conducted in the past decade. It has become clear that older adults with Alzheimer’s disease have lower vitamin D concentrations than others (Balion et al., 2012; Annweiler et al., 2013a). Similarly, hypovitaminosis D is associated with the presence of dementia in cross-sectional studies (Buell et al., 2010). Prospective longitudinal cohorts in older adults have also reported that hypovitaminosis D predicted increased incidence of dementia after 7 years of follow-up (Annweiler et al., 2011a). In contrast, high dietary intake of vitamin D (>800 UI/day reduced the incidence of Alzheimer’s disease after 7 years (Annweiler et al., 2012a). The relationship between vitamin D and dementia is highlighted during the advanced stages of the disease (Annweiler et al., 2011), but also from the prodromal stage (mild cognitive impairment, MCI) (Annweiler et al., 2012b) even though this minor neurocognitive disorder does not diminish the functional autonomy. Finally, the relationship between vitamin D and cognition was also found in people without dementia, with a linear relationship (Annweiler et al., 2009). The lower the concentration of vitamin D, the more impaired the cognitive performance (Oudshoorn et al., 2008). This direct association was found with both the global cognitive performance (Egen et al., 2012), the memory, and especially with the executive functions (Annweiler et al., 2013b). In other words, vitamin D is associated with cognitive performance in older adults even before the onset of dementia. It is thus crucial to appreciate, in older adults with or without dementia, what level of vitamin D is associated with impaired cognitive scores.

ANALYTICAL STUDY OF THE THRESHOLD OF SERUM 25OHD CONCENTRATION RELATED TO COGNITIVE DISORDERS

Table 1 summarizes the characteristics of the studies that have explored the association of cognitive scores with hypovitaminosis D defined as serum 25OHD concentration less than either 10, 20, or 30 ng/mL.

As illustrated, the results were mixed, with some studies having found an association between hypovitaminosis D and cognitive disorders (Wilkins et al., 2006; Buell et al., 2009; Annweiler et al., 2010b; Llewellyn et al., 2010, 2011; Hansen et al., 2011; Menant et al., 2012; Slomin et al., 2012), while others reported no association (Aung et al., 2006; Buell et al., 2009; Wilkins et al., 2009; Hansen et al., 2011; Menant et al., 2012). Of note, it was primarily the threshold at 10 ng/mL that was associated with cognition, whereas this was not the case with the threshold at 20 ng/mL. Additionally, the convincing results with the threshold at 30 ng/mL were constantly found in comparison with concentrations lower than 10 ng/mL, which reinforces the clinical value of the latter threshold with respect to cognition.

Highlighting that the threshold of 25OHD at 10 ng/mL is linked to cognition makes sense. Indeed, the brain is able to withstand degenerative lesions for a long time before expressing an objectified cognitive decline (Jack et al., 2010). In other words, occurrence of cognitive disorders means that the brain is already the seat of advanced neuronal damages. Precisely, since hypovitaminosis D occurs gradually, presenting with 25OHD concentration lower than 10 ng/mL means that hypovitaminosis D is chronic (Annweiler et al., 2011b), and has probably led to brain dysfunction for a long time. In line with this, it has already been shown that the lower the 25OHD concentration, the more severe the chronic diseases (Beauchet et al., 2012).

IMPLICATIONS FOR PRACTICE AND RESEARCH

The existing body of evidence provides proof that the threshold of 25OHD associated with cognitive status is around 10 ng/mL, the people with 25OHD concentration <10 ng/mL having a greater risk of cognitive disorders than those with 25OHD >10 ng/mL, and an even greater risk compared to those with 25OHD >30 ng/mL. The implications for practice and research are manifold. First, this finding supports the idea that chronic hypovitaminosis D is a risk factor for cognitive disorders, and may partially explain the onset of dementia among older adults. Second, it means that older adults with cognitive disorders likely have very low 25OHD concentrations and, thus, should receive...
Table 1 | Summary of the observational studies examining the association between cognitive scale scores and hypovitaminosis D using a threshold at 10, 20, or 30 ng/mL.

| Reference | Settings | Population | Subgroups of serum 25-hydroxyvitamin D | Association with cognitive scale scores? |
|-----------|----------|------------|----------------------------------------|------------------------------------------|
| **THRESHOLD 10 ng/mL** | | | | |
| Wilkins et al. (2006) | Location: Washington, DC, USA (38.9°N) | Community-dwellers | <10 Versus ≥20 ng/mL | Yes, with global cognitive performance |
| | | N = 80, 62.5% women | | |
| | | Mean age: 74.8 ± 7.7 years | | |
| | | 22.5% Black | | |
| | | Specificity: half with mild dementia, and half without dementia | | |
| Aung et al. (2006); CREST study | Location: Harris County, TX, USA (29.8°N) | Community-dwellers | <10 Versus ≥10 ng/mL | No, with global cognitive performance |
| | | N = 44, 63.6% women | | |
| | | Mean age: 76.1 ± 8.5 years | | |
| | | 38.6% White | | |
| | | Specificity: self-neglecting older adults referred by the adult protective services | | |
| Buell et al. (2009); NAME study | Location: Boston, MA, USA (42.2°N) | Community-dwellers | <10 Versus 10–20 ng/mL | No, with global cognitive performance |
| | | N = 1092, 75.9% women | | |
| | | Mean age: 75.0 ± 8.5 years | | |
| | | 34.9% Black | | |
| | | Specificity: older adults receiving home health services | | |
| Annweiler et al. (2010b); EPIDOS study | Location: France (Toulouse, 43.4°N; Montpellier, 43.6°N; Lyon, 45.5°N; Paris 48.5°N; Amiens, 49.9°N) | Community-dwellers | <10 Versus ≥10 ng/mL | Yes, with global cognitive performance |
| | | N = 752, 100% women | | |
| | | Mean age: 81.2 ± 3.5 years | | |
| | | Specificity: only older women | | |
| **THRESHOLD 20 ng/mL** | | | | |
| Wilkins et al. (2006) | Location: Washington, DC, USA (38.9°N) | Community-dwellers | 10–19.9 Versus ≥20 ng/mL | Yes, with global cognitive performance |
| | | N = 80, 62.5% women | | |
| | | Mean age: 74.8 ± 7.7 years | | |
| | | 22.5% Black | | |
| | | Specificity: half with mild dementia, and half without dementia | | |
| Aung et al. (2006); CREST study | Location: Harris County, TX, USA (29.8°N) | Community-dwellers | <20 Versus ≥20 ng/mL | No, with global cognitive performance |
| | | N = 44, 63.6% women | | |
| | | Mean age: 76.1 ± 8.5 years | | |
| | | Specificity: self-neglecting older adults referred by the adult protective services | | |
| Buell et al. (2009); NAME study | Location: Boston, MA, USA (42.2°N) | Community-dwellers | 10–20 Versus >20 ng/mL | No, with global cognitive performance |
| | | N = 1092, 75.9% women | | |
| | | Mean age: 75.0 ± 8.5 years | | |
| | | 34.9% Black | | |
| | | Specificity: older adults receiving home health services | | |

(Continued)
Table 1 | Continued

| Reference | Settings | Population | Subgroups of serum 25-hydroxyvitamin D | Association with cognitive scale scores? |
|-----------|----------|------------|----------------------------------------|-------------------------------------------|
| Wilkins et al. (2009) | Location: Washington, DC, USA (38.9°N) | Community-dwellers N = 60 Mean age: 75.0 ± 8.2 years 50.0% Black Specificity: either cognitively normal or mildly impaired cognition, without vitamin D supplementation | <20 Versus ≥20 ng/mL | No, with global cognitive performance |
| Hansen et al. (2011) | Location: Bergen, Norway (60.4°N) | N = 25, 100% men Mean age: 34.6 ± 9.4 years Specificity: only middle-aged men incarcerated in a Norwegian prison | <20 Versus ≥20 ng/mL | No, with information processing speed Yes, with information updating |
| Menant et al. (2012); Memory and Aging Study | Location: Sydney, NSW, Australia (33.5°S) | Community-dwellers N = 463, 53.4% women Mean age: 78.0 ± 4.6 years | ≤20 Versus >20 ng/mL | No, with global cognitive performance No, with information processing speed Yes, with mental shifting |
| Llewellyn et al. (2011); NHANES III | Location: USA (25.5°N – 47.3°N) | Community-dwellers N = 3325, 55.2% women Mean age: 73.7 ± 10.9 years 76% Black Specificity: only older adults | <10 Versus ≥30 ng/mL | Yes, with global cognitive performance Yes, with information processing speed Yes, with information updating Yes, with episodic memory |
| Llewellyn et al. (2010); InCHIANTI study | Location: Italy (Greve in Chianti, 43.6°N; Bagno a Ripoli, 43.8°N) | Community-dwellers N = 858, 49.4% women Mean age at baseline: 73.9 years Caucasian Specificity: older adults from a geographically confined area | <10 Versus ≥30 ng/mL | Yes, with global cognitive performance Yes, with information processing speed Yes, with mental shifting |
| Slinin et al. (2012); SOF study | Location: USA (Baltimore, MD, 39.3°N; Pittsburgh, PA, 40.4°N; Portland, OR, 45.6°N; Minneapolis, MN, 46.9°N) | Community-dwellers N = 5692, 100% women Mean age at baseline: 76.6 ± 4.7 years Caucasian Specificity: only older women | <10 Versus ≥30 ng/mL | Yes, with global cognitive performance Yes, with mental shifting |

**CONCLUSION**

In conclusion, older adults commonly have low serum vitamin D concentrations. For clinicians, it is useful to determine the level of vitamin D required to prevent the development of diseases. Regarding cognition, existing literature provides evidence that the threshold of 25OHD associated with cognitive disorders is somewhere around 10 ng/mL. Unfortunately no study has tested yet the three classical 25OHD thresholds simultaneously in relation to cognition. Prospective multicenter population-based cohort studies are desirable to address this issue specifically with a satisfactory level of evidence.

**AUTHOR CONTRIBUTIONS**

All authors meet all of the following criteria: (1) contributing to the conception and design, or analyzing and interpreting data;
Vitamin D and cognition

REFERENCES

Annweiler, C., Allali, G., Allain, P., Briderbaugh, S., Schott, A. M., Kressig, R. W., et al. (2009). Vitamin D and cognitive performance in adults: a systematic review. *Eur. J. Neurol.*, 16, 1083–1089. doi:10.1111/j.1468-1331.2009.02755.x

Annweiler, C., and Beauchet, O. (2011). Vitamin D metabolism: randomized clinical trials should be the next step. *Neuroendocrinology* 37, 249–258. doi:10.1159/000334177

Annweiler, C., Beauchet, O. (2013). Vitamin D and cognition: recommendations for future trials. *J. Am. Geriatr. Soc.*, 61, 1049–1050. doi:10.1111/jgs.12387

Annweiler, C., Fantino, B., Le Gall, D., Schott, A. M., Berrut, G., and Beauchet, O. (2011). Severe vitamin D deficiency is associated with advanced-stage dementia in geriatric inpatients. *J. Am. Geriatr. Soc.*, 59, 169–171. doi:10.1111/j.1532-5415.2010.03166.x

Annweiler, C., Llewellyn, D. J., and Beauchet, O. (2013a). Low serum vitamin D concentrations in Alzheimer’s disease: a systematic review and meta-analysis. *Neurology* 79, 1397–1405. doi:10.1212/WNL.0b013e31826e197f

Basha, B., Rao, D. S., Han, Z. H., and Parfitt, A. M. (2000). Osteomalacia due to vitamin D depletion: a neglected consequence of intestinal malabsorption. *J. Natl. Med. Assoc.* 102, 296–300. doi:10.3814/JNP2.20000460-X

Beauchet, O., Helard, L., Montero-Odasso, M., de Deckere, L., Berrut, G., and Annweiler, C. (2012). Hypovitaminosis D in geriatric inpatients: a marker of severity of chronic diseases. *Aging Clin. Exp. Res.* 24, 188–192. doi:10.3275/75838

Bischof-Ferrari, H. A., Giovannucci, E., Willett, W. C., Dietrich, T., and Dawson-Hughes, B. (2006). Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. *Am. J. Clin. Nutr.* 83, 1435S–1445S.

Buell, J. S., Thibault, V., Chen, K. C., Langh, M. C., Landfield, P. W., and Porter, N. M. (2001). Vitamin D hormone confers neuroprotection in parallel with downregulation of L-type calcium channel expression in hippocampal neurons. *J. Neurovirol.* 21, 98–108.

Brown, J., Bianco, J. I., McGrath, J. J., and Eyles, D. W. (2003). 1,25-Dihydroxyvitamin D3 induces nerve growth factor, promotes neurite outgrowth and inhibits mitosis in embryonic rat hippocampal neurons. *Neurosci. Lett.* 343, 139–143. doi:10.1016/S0304-3940(03)00303-3

Buell, J. S., Dawson-Hughes, B., Scott, T. M., Weiner, D. E., Dallal, G. E., Qui, W. Q., et al. (2010). 25-Hydroxyvitamin D, dementia, and cerebrovascular pathology in elders receiving home services. *Neurology* 74, 18–26. doi:10.1212/WNL.0b013e3181811867

Buell, J. S., Scott, T. M., Dawson-Hughes, B., Dalal, G. E., Rosenberg, I. H., Folstein, M. F., et al. (2009). Vitamin D is associated with cognitive function in elders receiving home health services. *J. Gerontol. A Biol. Sci. Med. Sci.* 64, 888–895. doi:10.1093/gerona/glp032

Dusso, A. S., Brown, J., and Slapolsky, E. (2005). Vitamin D. *Am. J. Physiol.* 289, F8–F28.

Etgen, T., Sander, D., Bickel, H., Sander, K., and Forrest, H. (2012). Vitamin D deficiency, cognitive impairment and dementia: a systematic review and meta-analysis. *Dement. Geriatr. Cogn. Disord.* 33, 297–305. doi:10.1159/000349372

Hansen, A. L., Dahl, L., Bakke, L., and Thayer, J. F. (2011). Vitamin D and executive function in elders receiving home health services. *J. Gerontol. A Biol. Sci. Med. Sci.* 66, 59–65. doi:10.1093/gerona/gls017

Hollis, B. W., and Wagner, C. L. (2004). Vitamin D requirements during lactation: high-dose maternal supplementation as therapy to prevent hypovitaminosis D for both the mother and the nursing infant. *Am. J. Clin. Nutr.* 80, 1752S–1758S.

Holmøy, T., Moen, S. T., Gundersen, T. A., Holick, M. F., Fainardi, E., Castellazzi, M., et al. (2009). 25-Hydroxyvitamin D in cerebrospinal fluid during relapse and remission of multiple sclerosis. *Mult. Scler.* 15, 1280–1285. doi:10.1177/1352458509107008

Ibi, M., Sawada, H., Nakashima, M., Kume, T., Katsuki, H., Kaneko, S., et al. (2001). Protective effects of 1α,25-(OH)2D3 against the neurotoxicity of glutamate and reactive oxygen species in mesencephalic culture. *Neuropharmacology* 40, 761–771. doi:10.1016/S0028-9098(01)00090-0

Ito, S., Ohtsuki, S., Nezu, Y., Kitabashi, Y., Murata, S., and Terasaki, T. (2011). 1α,25-Dihydroxyvitamin D3 enhances cerebral clearance of human amyloid-β peptide(1-40) from mouse brain across the blood-brain barrier. *Fluids Barriers CNS* 8, 20. doi:10.1186/2045-8118-8-20

Jackson, R. C., Jr., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., et al. (2010). Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. *Lancet Neurol.* 9, 119–128. doi:10.1016/S1474-4222(09)70299-6

Kalauf, A. V., and Toshimah, P. (2007). Neurorodhoric hormone vitamin D and its utility in clinical nutrition. *Curr. Opin. Clin. Nutr. Metab. Care* 10, 12–19. doi:10.1097/MCN.0b013e3280b9ca18

Llewellyn, D. J., Lang, I. A., Langa, R. M., and Melzer, D. (2011). Vitamin D and cognitive impairment in the elderly U.S. population. *J. Gerontol. A Biol. Sci. Med. Sci.* 66, 59–65. doi:10.1093/gerona/gq1485

Llewellyn, D. J., Lang, I. A., Langa, K. M., Muniz-Terrera, G., Phillips, C. L., Cherubini, A., et al. (2010). Vitamin D and risk of cognitive decline in elderly persons. *Arch. Intern. Med.* 170, 1135–1141. doi:10.1001/archinternmed.2010.173

Lo, C. W., Paris, P., Clemens, T. L., Nolan, J., and Holick, M. F. (1985). Vitamin D absorption in healthy subjects and in patients with intestinal malabsorption syndromes. *Am. J. Clin. Nutr.* 42, 644–649.

Masoumi, A., Goldenson, B., Ghiramat, S., Avagyan, H., Zigli, I., Abel, K., et al. (2009). 1α,25-dihydroxyvitamin D3 interacts with curcuminoids to stimulate amyloid-beta clearance by macrophages of Alzheimer’s disease patients. *J. Alzheimers Dis.* 17, 703–717. doi:10.3233/JAD-2009-1080

Menati, J. C., Close, J. C., Delbaere, K., Sturmieks, D. I., Trolor, I., Sachdev, P. S., et al. (2012). Relationships between serum vitamin D levels, neuromuscular and neuropsychological function and falls in older men and women. *Osteoporois. Int.* 23, 981–988. doi:10.1007/s00198-011-1657-7

Moore, M. E., Piazza, A., McCarthy, Y., and Lynch, M. A. (2005). Evidence that vitamin D3 reverses age-related inflammatory changes in the rat hippocampus. *Biochem. Soc. Trans.* 33, 577–578. doi:10.1042/BST030573

Oudshoorn, C., Mattace-Raso, F. U., van der Velde, N., Colon, E. M., and van der Cammen, T. J. (2008).

(2) drafting the article or revising it critically for important intellectual content; and (3) approving the final version to be published.
Higher serum vitamin D3 levels are associated with better cognitive test performance in patients with Alzheimer’s disease. Dement. Geriatr. Cogn. Disord. 25, 539–543. doi:10.1159/000134382

Slinin, Y., Paudel, M., Taylor, B. C., Ishani, A., Rossom, R., Yaffe, K., et al. (2012). Association between serum 25(OH) vitamin D and the risk of cognitive decline in older women. J. Gerontol. A Biol. Sci. Med. Sci. 67, 1092–1098. doi:10.1093/gerona/gls075

Wilkins, C. H., Birge, S. J., Sheline, Y. I., and Morris, J. C. (2009). Vitamin D deficiency is associated with worse cognitive performance and lower bone density in older African Americans. J. Natl. Med. Assoc. 101, 349–354.

Wilkins, C. H., Sheline, Y. I., Roe, C. M., Birge, S. J., and Morris, J. C. (2006). Vitamin D deficiency is associated with low mood and worse cognitive performance in older adults. Am. J. Geriatr. Psychiatry 14, 1032–1040. doi:10.1097/01.JGP.0000240986.74642.7c

World Health Organization. (2003). Prevention and Management of Osteoporosis: Report of a WHO Scientific Group. Geneva: World Health Organization.

Yu, J., Gattoni-Celli, M., Zhu, H., Bhat, N. R., Sambamurti, K., Gattoni-Celli, S., et al. (2011). Vitamin D3-enriched diet correlates with a decrease of amyloid plaques in the brain of AbetaPP transgenic mice. J. Alzheimers Dis. 25, 295–307. doi:10.3233/JAD-2011-101986

Zhou, C., Assem, M., Tay, J. C., Blumberg, B., Schuetz, E. G., and Thummel, K. E. (2006). Steroid and xenobiotic receptor and vitamin D receptor crosstalk mediates CYP24 expression and drug-induced osteomalacia. J. Clin. Invest. 116, 1703–1712. doi:10.1172/JCI27793

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 12 January 2014; accepted: 31 March 2014; published online: 15 April 2014.

Citation: Annweiler C and Beauchet O (2014) Vitamin D in older adults: the need to specify standard values with respect to cognition. Front. Aging Neurosci. 6:72. doi: 10.3389/fnagi.2014.00072

This article was submitted to the journal Frontiers in Aging Neuroscience.

Copyright © 2014 Annweiler and Beauchet. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.